Blueprint Medicines Corporation (NASDAQ:BPMC) insider Kate Haviland sold 5,449 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $66.44, for a total value of $362,031.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Kate Haviland also recently made the following trade(s):

  • On Monday, September 18th, Kate Haviland sold 6,356 shares of Blueprint Medicines Corporation stock. The shares were sold at an average price of $60.03, for a total value of $381,550.68.

Shares of Blueprint Medicines Corporation (BPMC) traded up 2.34% on Tuesday, reaching $67.66. The company’s stock had a trading volume of 190,490 shares. The stock’s market capitalization is $2.65 billion. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $71.67. The stock has a 50-day moving average of $58.24 and a 200 day moving average of $48.54.

Blueprint Medicines Corporation (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.11). The firm had revenue of $5.89 million during the quarter, compared to the consensus estimate of $5.96 million. Blueprint Medicines Corporation had a negative net margin of 388.91% and a negative return on equity of 45.58%. The firm’s quarterly revenue was down 16.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.70) earnings per share. On average, analysts expect that Blueprint Medicines Corporation will post ($3.66) EPS for the current year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/10/kate-haviland-sells-5449-shares-of-blueprint-medicines-corporation-bpmc-stock.html.

A number of research analysts have issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and set a $56.00 price target on shares of Blueprint Medicines Corporation in a research report on Tuesday, September 5th. Canaccord Genuity reiterated a “buy” rating and set a $56.00 price target on shares of Blueprint Medicines Corporation in a research report on Monday, September 11th. BidaskClub upgraded Blueprint Medicines Corporation from a “hold” rating to a “buy” rating in a research report on Tuesday, June 20th. Zacks Investment Research upgraded Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $79.00 price target (up previously from $64.00) on shares of Blueprint Medicines Corporation in a research report on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. Blueprint Medicines Corporation has a consensus rating of “Buy” and a consensus price target of $63.47.

A number of institutional investors and hedge funds have recently made changes to their positions in BPMC. Ameritas Investment Partners Inc. boosted its position in Blueprint Medicines Corporation by 68.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,391 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Blueprint Medicines Corporation in the 1st quarter valued at $201,000. Fred Alger Management Inc. bought a new position in Blueprint Medicines Corporation in the 2nd quarter valued at $203,000. SG Americas Securities LLC boosted its position in Blueprint Medicines Corporation by 23.3% in the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 778 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in Blueprint Medicines Corporation by 4,457.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,238 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 4,145 shares during the last quarter. Hedge funds and other institutional investors own 90.71% of the company’s stock.

About Blueprint Medicines Corporation

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Insider Buying and Selling by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.